Tier-2 and Tier-3 cities are becoming the new epicenters of India’s healthcare boom, as private equity finds gold in single-specialty hospital chains.
It’s not the sprawling metros but the quieter corners of India that are catching the attention of private equity (PE) giants. From IVF clinics in Patna to dialysis centres in Guwahati, a seismic shift is underway in India’s healthcare investment map. The playbook is clear: bet big on focussed, single-speciality hospital chains and take the battle for market share where it’s underserved and overdue—Tier-II and III cities.
According to Avendus, more than 40 per cent of PE investments in Indian healthcare since 2019 have gone to single-specialty players—a dramatic jump from just over 15 per cent between 2015 and 2018. What changed? The realisation is that these niche medical models offer scale, speed, and strong unit economics—without the capital-intensive baggage of large multi-speciality setups. From IVF and oncology to nephrology and eyecare, these focused formats are not just surviving—they’re thriving.
Behind this investor pivot lies a strategic cocktail of precision, profit, and predictability. Single-specialty hospitals are built to do one thing and do it well. Smaller footprints (40–50 beds on average), quick breakeven cycles, and streamlined operations make them attractive from a return-on-equity standpoint. The average capital outlay per facility stands at Rs 30–40 crore, making these ventures both scalable and capital-efficient. Compare that to multi-speciality hospitals, where the average size exceeds 250 beds and the break-even horizon stretches longer.
Players like Asia Healthcare Holdings (AHH) have become flag-bearers of this movement. Focussed on verticals like women and child care, fertility, oncology, and urology, AHH’s portfolio has not only expanded to 60 cities but has also delivered consistent EBITDA growth and enviable ROI benchmarks. It’s no longer about just building hospitals—it’s about building repeatable, efficient care models that fit perfectly into the underserved contours of India.
Between 2020 and early 2025, the sector saw 24 PE/VC deals amounting to $1.8 billion, of which $1.2 billion came in just the last two years, according to Grant Thornton. This is not a fleeting trend—it’s a momentum play, powered by shifting demographics, improved affordability, and growing specialist availability in smaller towns.
It also helps that these verticals carry lower clinical risk, high patient turnover, and a lower chance of cross-infection, making them operationally lean and patient-friendly. Add to that the impact of technology—from AI-enabled patient query bots to RFID-tagged IVF samples—and the clinical edge sharpens even further.
For B2B players in the healthcare ecosystem—from real estate developers to medical device suppliers, diagnostics labs to IT service providers—the signal is loud and clear. The future is not just in big hospitals or big cities. It’s in focused care, delivered at scale, in places the market once overlooked. PE firms have read the prescription—and they’re writing cheques to match.
In India’s next healthcare chapter, the heartland isn’t just healing—it is hot property.
